Loading patent…
AssigneeBoard of Trustees of the University of Arkansas
InventorsSamuel M. Owens, Frank Ivy Carroll, Philip Abraham
Estimating the term…
The invention includes synthetic immunochemical haptens for the generation of antibodies, the antibodies, and the medical treatment applications for using the antibodies. The antibodies are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants, and will have insignificant cross-reactivity with endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses or fetus from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.
A monoclonal antibody that specifically recognizes a class or stimulant or hallucinogenic drug of abuse comprising d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, and (+/−) 3,4-methylenedioxyamphetamine, wherein said monoclonal antibody is generated by a hapten comprising (S)- or (R)-3-(5′-Carboxypentyloxy) methamphetamine hydrochloride.
An antibody fragment that specifically recognizes a class of stimulant or hallucinogenic drug of abuse comprising d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, and (+/−) 3,4-methylenedioxyamphetamine, wherein said antibody fragment is part of a monoclonal antibody generated by a hapten comprising (S)- or (R)-3-(5′-Carboxypentyloxy) methamphetamine hydrochloride.
Dependencies are inferred from the claim text.